secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2024-12-09T23:59:59+00:00
Accession:  0000950170-24-134342
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics announces FDA acceptance of NDA for paltusotine in acromegaly; PDUFA Sept 25, 2025
--------------------------------------------------------------------------------

- FDA accepted Crinetics' NDA for once-daily oral paltusotine for adult acromegaly patients.
- PDUFA target action date set for September 25, 2025; no advisory committee meeting planned.
- NDA included Phase 3 PATHFNDR-1 and PATHFNDR-2 trials evaluating safety and efficacy.
- Paltusotine granted Orphan Drug Designation by FDA in July 2020 for acromegaly.
- If approved, paltusotine would be first once-daily oral SST2 nonpeptide agonist for acromegaly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024134342/0000950170-24-134342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017024134342/crnx-20241209.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-134342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer